LinkOPH

The U.S. Senate Committee on Health, Education, Labor and Pensions adopted legislation today designed to speed up development of genetically targeted drugs for patients with rare and serious or life-threating conditions.The “Advancing Targeted Therapies for Rare Diseases Act of 2015” (S. 2030), sponsored by Sens. Michael Bennet, D-Colo., Richard Burr, R-N.C., Elizabeth Warren, D-Mass., and Orrin Hatch, R-Utah, will allow drug companies seeking approval of a candidate therapy to leverage data from previously approved drug applications and to maximize the use of certain scientific methods, such as surrogate endpoints, to facilitate drug development.

Read more →

Dry eye is a problem that every ophthalmologist faces on a daily basis. It is one of the most frequent causes for patients to visit the ophthalmologist. Dry eye is a progressive disease, so the longer it goes untreated, the worse the symptoms become. D…

Read more →

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Aziz Mottiwala, vice president of marketing at Allergan, discusses the company’s “franchise approach” to the glaucoma space in which it would like to ensure it has a full complement of pharmaceutical and surgical device options for treating glaucoma.

Read more →

DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/p5xgrv/age_related) has announced the addition of the “Age Related Macular Degeneration – Pipeline Review, H2 2015” report to their offering. This report provides…

Read more →

SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (“Second Sight” or “the Company”) (Nasdaq:EYES), a developer, manufacturer and marketer of implantable visual prosthetics to restore some useful vision to blind patients, today announced plans to expand into South America by signing an exclusive agreement with Tecnosalud S.A. (“Tecnosalud”) to distribute the Argus® II Retinal Prosthesis System (“Argus II”) in Argentina. “We are excited to partner with Tecnosalud for our expans

Read more →

MIAMI — Harry W. Flynn Jr., MD, discussed the newly published and continuing trials of the Diabetic Retinopathy Clinical Research Network at Angiogenesis, Exudation, and Degeneration 2016.Protocol S, which was recently published, showed that intravitreal Lucentis (ranibizumab, Genentech) was not inferior to panretinal photocoagulation for diabetic macular edema and resulted in better visual acuity over 2 years. The ranibizumab group had a higher chance of a 10-letter score improvement or better, while the PRP group had a higher chance of visual acuity worsening by 10 letters or more, as well as a higher chance for pars plana vitrectomy and vitreous hemorrhage.

Read more →